-
Beware Of Deception By Drug Companies: Former NEJM Editor In Chief
Prescription Drug Companies Have Used Deceptive Practices: NJ Public Interest Research Group Going back in time a bit, the March 1, 2005 edition of Bottom Line/Health featured an excellent article for patients and doctors,…
-
Ketek: Side-Effects May Outweigh Its Benefits
And Sanofi-Aventis Suspends Enrollment In A Pediatric Clinical Trial In May and June 2006 there was a continuing debate on several levels about whether or not Ketek (telithromycin) should be withdrawn from the market…
-
Should The Popular Asthma Drug Advair Be Pulled From The Market?
Study Finds Increased Risk Of Serious Side Effects For A Broad Range Of Users A study published in June 2006 by a leading medical journal concludes that GlaxoSmithKline’s popular asthma drug Advair is perhaps…
-
Natrecor: A Definitive Safety Study Is Long Overdue
Off-label Use Of Natrecor Continues To Be A Problem A year ago two medical journal articles raised serious safety issues about Natrecor; in summary: (1) a 50% increased risk of kidney damage or renal…
-
Merck’s New Vioxx Web Site: What Is This About?
The Drug Company Wants You To Know What It Thinks About The Vioxx Litigation Merck & Co. has turned to the Internet in order to further disseminate their positions concerning the ongoing Vioxx litigation…
-
Antibiotic Ketek: FDA Staff Recommends “Black-box” Warning
As Of May 1, 2006 There Are 23 Reports Of Serious Liver Injury, Including 12 Cases Of Liver Failure, In U.S. After finding the antibiotic Ketek (telithromycin) has been associated with 12 cases of…
